| Miss Gladys Anne Causaren Ambion, RPH | |
|
12141 Gilbert St, Garden Grove, CA 92841-3503 | |
| (714) 400-8679 | |
| Not Available |
| Full Name | Miss Gladys Anne Causaren Ambion |
|---|---|
| Gender | Female |
| Speciality | Assisted Living Facility |
| Location | 12141 Gilbert St, Garden Grove, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962025031 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 81839 (California) | Secondary |
| 310400000X | Assisted Living Facility | 306006272 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Miss Gladys Anne Causaren Ambion, RPH 12141 Gilbert St, Garden Grove, CA 92841-3503 Ph: (714) 400-8679 | Miss Gladys Anne Causaren Ambion, RPH 12141 Gilbert St, Garden Grove, CA 92841-3503 Ph: (714) 400-8679 |
News Archive
Data published in the January issue of Innovations in Clinical Neuroscience, www.psychiatrymmc.com, suggest when L-methylfolate, a medical food available commercially as Deplin®, and by prescription, is used for dietary management of depression in combination with an antidepressant drug at the start of depression therapy, it results in significantly more patients experiencing major improvement and more rapid improvement than antidepressant monotherapy alone.
Patients battling cancer have a better experience of care at hospitals that employ more cancer specialist nurses.
CVS Caremark announced today that the Pharmacy Benefit Management Institute (PBMI) awarded the company and its PBM client ArcelorMittal, the world's largest steel company, the 2011 Rx Benefit Innovation Award. The award recognizes the Pharmacy Advisor program, which was developed by CVS Caremark to manage costs, improve medication adherence and close gaps in care for members with diabetes.
Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density.
The International Association for the Study of Lung Cancer (IASLC) has taken a proactive role in advancing discussions with the international lung cancer community on how we should take lung cancer screening forward.
› Verified 3 days ago